drugset / Trial / NCT01536145
CP-751,871 Treatment For Patients With Multiple Myeloma
NaSingle-groupOpen-labelTreatment
Summary
This study represents the first-in-human study for CP-751,871. The study aimed to define the safety, tolerability, and maximum tolerated dose of CP-751,871 in patients with multiple myeloma through a dose escalation design.
Timeline
- Start
- 2003-12
- Primary completion
- 2008-06
- Completion
- 2008-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Figitumumab | Monoclonal antibody | 0.025 mg/kg | Intravenous |
| Subject | Figitumumab | Monoclonal antibody | 20 mg/kg | Intravenous |